Jenburkt Pharmaceuticals Ltd. Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013
For the nine months, the company reported net sales/income from operations (net of excise duty) of INR 562.68 million against INR 520.785 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 76.337 million against INR 64.859 million a year ago. Profit from ordinary activities before tax was INR 72.465 million against INR 64.640 million a year ago. Net profit was INR 51.965 million or INR 11.18 per basic and diluted share against INR 45.440 million or INR 9.77 per basic and diluted share a year ago.